ALK's shares rose 7.6% after the company reported better-than-expected Q1 revenue growth and margin expansion, driven by record tablet sales and a positive update on its peanut allergy Phase II trial.

• Q1 revenue increased 18% to DKK 1.8 billion, led by double-digit growth across all major regions except Japan.
• Tablet sales hit a milestone, surpassing DKK 1 billion for the quarter, growing 26% in both Europe and North America, despite a 17% decline in international markets due to shipment timing in Japan.
• Gross margin improved 2 percentage points to 69%, supported by a favorable product mix and seasonality with higher-margin European tablets.
• Operating profit grew 22%, with EBIT margin expanding to 32%, despite a 23% rise in capacity costs reflecting investments in growth initiatives.
• The Phase II ALLIANCE trial for the peanut allergy tablet showed statistically significant efficacy, providing a strong strategic catalyst going forward.